Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Research Report 2020 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market."

ITP (idiopathic thrombocytopenic purpura) is a rare disease with low affliction rates. This disease leads to excessive bruising or bleeding due to the lack of blood platelets. It is also known as immune thrombocytopenia and can affect children and adults alike.

Increasing demand for combination therapies therapy is expected to fuel the future growth of the ITP therapeutics market. Clinical evidence suggests that combination therapies entail relatively lower side effects, are cost-effective and display higher response rates in patients.

The global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is valued at xx million US$ in 2020 is expected to reach xx million US$ by the end of 2029, growing at a CAGR of xx% during 2021-2029.

In Jan 2020,
 Instituto Grifols S.A. received marketing authorization valid throughout the European Union for Tavlesse which is a medicine for treating adults with chronic immune thrombocytopenia. It is for use when other treatments have not worked.

Chronic immune thrombocytopenia, previously called idiopathic thrombocytopenic purpura (ITP), is a long-term condition in which the immune system (the body’s defences) destroys healthy platelets in the blood. Platelets are needed to form clots and stop bleeding. Patients with the disease have low platelet counts and may bruise or bleed easily.

Tavlesse was found modestly effective for patients with immune thrombocytopenia when other treatments had not worked well enough and for whom there is no alternative treatment. Tavlesse can have serious side effects but they can be managed by taking precautions and reducing the dose. The European Medicines Agency therefore decided that Tavlesse’s benefits are greater than its risks and it can be authorised for use in the EU.

Tavlesse contains the active substance fostamatinib. Fostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia (ITP) in patients who have had insufficient response to previous therapy. The active metabolite of fostamatinib, R406, inhibits signal transduction by Fcgamma receptors involved in the antibody-mediated destruction of platelets by immune cells in chronic ITP. This results in increased platelet counts in this population.

This report focuses on Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics volume and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market size by analyzing historical data and future prospects.

Regionally, this report focuses on several key regions: North America, Europe, China, and Japan.
At the company level, this report focuses on the production capacity, ex-factory price, revenue, and market share for each manufacturer covered in this report.

The following manufacturers are covered:

 	
Roche
 	
Amgen Inc
 	
Grifols Biologicals Inc.
 	
GlaxoSmithKline Plc
 	
Novartis
 	
NuFactor
 	
ADMA Biologics
 	
Intas
 	
Aspar Pharmaceuticals
 	
Promacta
 	
Midas-Pharma

Segment by Regions

 	
North America
 	
Europe
 	
China
 	
Japan

Segment by Type

 	
Corticosteroids
 	
Intravenous Immunoglobulin (IVIG)
 	
Anti-D Immunoglobulin
 	
Thrombopoietin Receptor Agonists (TPO-RA)
 	
Others

Segment by Application

 	
Hospitals
 	
Clincs
 	
Others